BEIQING PAN, M.D.
Hematology & Oncology Physician in BRIDGEWATER, New Jersey. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
BEIQING PAN, M.D. reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 969 Medicare Part D claims in 2023.
- 100/100
- MIPS score · +17 vs avg
- 969
- Part D claims, 2023
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
BEIQING PAN, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
100 Top 7% higher than 93% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
BEIQING PAN, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about BEIQING PAN, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in New Jersey
How Hematology & Oncology Physician compares to other specialties among New Jersey providers
Hematology & Oncology Physician share within New Jersey
Hematology & Oncology Physician is one of the more visible NUCC categories in New Jersey
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
BEIQING PAN, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 100/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) — 100/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Specialty volume Hematology & Oncology Physician US NPIs
100/100 MIPS final score — 16.9 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Hematology & Oncology Physician.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
BEIQING PAN, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 1200 US HIGHWAY 22 STE 3, BRIDGEWATER, NJ, 08807, with a listed phone of (732) 390-7750. NPI 1881910263 was issued on 04/11/2010. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what PAN most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 969 prescription claims written by this provider, covering 159 Medicare beneficiaries and totaling roughly $2.5 million in drug spend, with an opioid prescribing rate of 9.4%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year, compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1881910263 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 04/11/2010 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm BEIQING PAN, M.D.'s current license status, disciplinary history, and board certifications with the New Jersey State Board of Medical Examiners in New Jersey before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where BEIQING PAN, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) — CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for BEIQING PAN, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$152
Largest payer
Regeneron Healthcare Solutions, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,546
- Total Day Supply
- 44,178
- Generic Drug Cost
- $410K
- Opioid Claims
- 91 (9.4% rate)
Patient Demographics
- Average Patient Age
- 74.3 years
- Avg HCC Risk Score
- 2.18
- Gender Split
- 62% female / 38% male
- Age Distribution
- <65: 19, 65-74: 58, 75-84: 55, 85+: 27
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What BEIQING PAN, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Eliquis
Eliquis
150 claims
- Anastrozole
Anastrozole
93 claims
- Warfarin Sodium
Warfarin Sodium
76 claims
- Procrit 54
Procrit
54 claims
- Aranesp 41
Aranesp
41 claims
- Oxycodone Hcl 33
Oxycodone Hcl
33 claims
- Oxycontin 26
Oxycontin
26 claims
- Ibrance 24
Ibrance
24 claims
| Drug | Claims |
|---|---|
| Eliquis Apixaban | 150 |
| Anastrozole | 93 |
| Warfarin Sodium | 76 |
| Procrit Epoetin Alfa | 54 |
| Aranesp Darbepoetin Alfa In Polysorbat | 41 |
| Oxycodone Hcl | 33 |
| Oxycontin Oxycodone Hcl | 26 |
| Ibrance Palbociclib | 24 |
| Lenalidomide | 24 |
| Neulasta Pegfilgrastim | 23 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How BEIQING PAN, M.D. fits within the Hematology & Oncology Physician landscape nationally.
BEIQING PAN, M.D.'s 969 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in New Jersey
Other clinicians with the same primary specialty enrolled in New Jersey, drawn from the same CMS NPPES roster as PAN.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New Jersey
Frequently Asked Questions
What is BEIQING PAN, M.D.'s specialty? ▼
How much does BEIQING PAN, M.D. prescribe under Medicare Part D? ▼
What is BEIQING PAN, M.D.'s Medicare quality score? ▼
Where is BEIQING PAN, M.D. located? ▼
What is BEIQING PAN, M.D.'s NPI number? ▼
Does BEIQING PAN, M.D. prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does BEIQING PAN, M.D. prescribe most often? ▼
Does BEIQING PAN, M.D. accept Medicare? ▼
How can I verify BEIQING PAN, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology